The 4.5 kDa tribranched anionic PEG was chosen for conjugation to two specific hGHR antagonist sites to produce a smaller hGH antagonist with the potential to have greater tumor penetration than the antagonist with the larger 40 kDa PEG (40). This evidence concerns the gene GH1 and neoplasm.